Altimmune

ALT

Biotechnology · Healthcare

Exchange

NASDAQ

Winston Score

Winston is serious

Below-average fundamentals — multiple weak pillars.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Weak

Growth

Strong

Cash Flow

Weak

Stability

Data not available

Valuation

Data not available

Track this stock — start free trial

Winston Score History

The full picture

Altimmune is a small biotech company focused on developing drugs to treat obesity and liver disease. Its main drug candidate is pemvidutide, a molecule designed to help people lose weight and reduce fat in the liver. The company does not yet sell any approved products — it is still running clinical trials to test whether its drugs are safe and effective.

Altimmune makes no product revenue yet and funds its operations through stock offerings and partnerships. It is based in Gaithersburg, Maryland, and operates primarily in the United States, with a market cap of roughly $300 million. The company's future depends almost entirely on the clinical success of pemvidutide, which is competing in the crowded GLP-1 weight-loss drug market against much larger companies like Novo Nordisk and Eli Lilly. If trial results disappoint or funding runs short, the company faces serious risk of significant losses for shareholders.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+820.0% YoY

YoY Growth Rate

Revenue accelerating

EPS Growth

+59.3% YoY

YoY Growth Rate

EPS growth accelerating

Insider Activity

5.6%ownership

↑ Rising

Insiders increasing their stake — aligned with shareholders

Cash Runway

~6 years

$519M cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

$519M cash & investments at current burn rate

Revenue accelerating

Altimmune grew revenue 820% year-over-year and the growth rate is speeding up. That's the kind of momentum growth investors look for — the question is whether margins can follow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

50.0%

Healthy — 50.0% gross margin

Profit after running costs

Operating Margin

-57019.6%

Losing money on operations — -57019.6%

Return on the money invested

ROCE

-21.1%

Weak — -21.1% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+285.0%

Fast-growing sales (+285.0% YoY)

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

8/8 quarters

Every recent quarter grew earnings vs last year

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

-93076.6%

Burning cash (-93076.6%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial